Danaher Corporation Dossier

Danaher Corporation generated $6.053 billion in revenue and $948 million in net earnings during the third quarter of fiscal year 2025, driven primarily by resilient demand within its diagnostics and life sciences segments.

Financial Highlights

* Third Quarter 2025 Revenue: $6.053 billion

* Q3 2025 Gross Profit Margin: 59.72%

* Q3 2025 Operating Cash Flow: $1.662 billion

* Q3 2025 Non-GAAP Free Cash Flow: $1.37 billion

* Q3 2025 Non-GAAP Adjusted Diluted EPS: $1.89

* Full Year 2025 Adjusted EPS Guidance: $7.70 to $7.80

* Q3 2025 R&D Investment: $418 million

* Market Capitalization: $156.12 billion

Danaher Corporation continues to leverage its proprietary Danaher Business System to optimize operations across its three core segments: Biotechnology, Life Sciences, and Diagnostics. The company reported a gross profit margin of 59.72% for the quarter, underscoring the efficiency of its operational model amidst complex market conditions. The firm maintains a strong liquidity position, evidenced by $1.662 billion in operating... Sign in / Sign up to learn more about Danaher Corporation

Continue your research by chatting with our AI financial analyst about Danaher Corporation. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given Danaher Corporation's strong Q3 FY2025 gross margin of 59.72%, how are the differing core growth rates across its segments (6.5% in Biotechnology vs. -1.0% in Life Sciences) impacting overall profitability, and what specific Danaher Business System initiatives are being prioritized to restore growth in the underperforming Life Sciences segment?
• Management has identified a potential $50-$100 million headwind in Danaher Corporation's China diagnostics business for the upcoming year. What are the primary market or policy factors driving this challenge, and how might it affect the company's ability to achieve its full-year FY2025 guidance for low-single-digit core revenue growth?
• With strong free cash flow generation of $1.37 billion in Q3 FY2025 but no major acquisitions completed in the first nine months of the year, how should investors assess Danaher Corporation's capital deployment strategy? What types of targets in high-growth markets like bioprocessing and genomics would be most accretive?
• Danaher Corporation's FY2025 guidance projects adjusted EPS between $7.70 and $7.80. Considering the slowdown in the Life Sciences segment and weakness in China, what are the key performance indicators that must be met in the final quarter of FY2025 for the company to achieve the high end of this guidance?
• The Danaher Business System (DBS) is cited as a key driver of efficiency. How can the impact of DBS be quantified in Danaher Corporation's FY2025 financial performance, particularly in maintaining high margins and strong free cash flow conversion despite macroeconomic headwinds and varied segment performance?